{"id":"NCT02487030","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection","officialTitle":"A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-09-07","primaryCompletion":"2016-11-11","completion":"2017-02-04","firstPosted":"2015-07-01","resultsPosted":"2017-12-14","lastUpdate":"2018-11-16"},"enrollment":255,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection"],"interventions":[{"type":"DRUG","name":"LDV/SOF","otherNames":["HarvoniÂ®","GS-5885/GS-7977"]},{"type":"DRUG","name":"RBV","otherNames":[]}],"arms":[{"label":"LDV/SOF 8 wk TN (Cohort 1, Group 1)","type":"EXPERIMENTAL"},{"label":"LDV/SOF+RBV 8 wk TN (Cohort 1, Group 2)","type":"EXPERIMENTAL"},{"label":"LDV/SOF 12 wk TN (Cohort 1, Group 3)","type":"EXPERIMENTAL"},{"label":"LDV/SOF+RBV 12 wk TN (Cohort 1, Group 4)","type":"EXPERIMENTAL"},{"label":"LDV/SOF+RBV 12 wk TE (Cohort 2)","type":"EXPERIMENTAL"},{"label":"LDV/SOF 12 wk TE (Cohort 3, Group 1)","type":"EXPERIMENTAL"},{"label":"LDV/SOF+RBV 12 wk TE (Cohort 3, Group 2)","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to evaluate the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed dose combination (FDC) with or without ribavirin (RBV) in Egyptian adults with chronic genotype 4 hepatitis C virus (HCV) infection.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)","timeFrame":"Posttreatment Week 12","effectByArm":[{"arm":"LDV/SOF 8 wk TN (Cohort 1, Group 1)","deltaMin":95.3,"sd":null},{"arm":"LDV/SOF + RBV 8 wk TN (Cohort 1, Group 2)","deltaMin":90.5,"sd":null},{"arm":"LDV/SOF 12 wk TN (Cohort 1, Group 3)","deltaMin":97.7,"sd":null},{"arm":"LDV/SOF + RBV 12 wk TN (Cohort 1, Group 4)","deltaMin":97.6,"sd":null},{"arm":"LDV/SOF 12 wk TE (Cohort 3, Group 1)","deltaMin":94.4,"sd":null},{"arm":"LDV/SOF + RBV 12 wk TE (Cohort 3, Group 2)","deltaMin":100,"sd":null},{"arm":"LDV/SOF + RBV 12 wk SOF or LDV/SOF Experienced (Cohort 2)","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":4},"locations":{"siteCount":4,"countries":["Egypt"]},"refs":{"pmids":["29666174"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":43},"commonTop":["Headache","Fatigue","Dyspepsia","Anaemia","Bronchitis"]}}